ライフサイエンスコーパス: obesity

1 d by a high accumulation of body fat (severe obesity).

2 inflammatory conditions including aging and obesity.

3 he lean state and metabolic dysregulation in obesity.

4 adolescent adiposity and risk of overweight/obesity.

5 erebrovascular dysfunction despite prolonged obesity.

6 f too much fat and to protect adults against obesity.

7 ting pandemic of metabolic disease driven by obesity.

8 as rheumatoid arthritis, liver fibrosis, or obesity.

9 ity is reduced in breast epithelial cells in obesity.

10 ck Children (2002-2011), excluding prevalent obesity.

11 reatment of drug addiction, anxiety, pain or obesity.

12 growth restriction (IUGR) leads to offspring obesity.

13 etween inflammation and the comorbidities of obesity.

14 inhibits lipolysis and promotes diet-induced obesity.

15 of meals are also potential risk factors for obesity.

16 increasing energy expenditure to counteract obesity.

17 a novel therapeutic target for patients with obesity.

18 k indirectly through their relationship with obesity.

19 ls display distinct metabolic adaptations to obesity.

20 could be a potential therapeutic target for obesity.

21 een implicated in substance use disorder and obesity.

22 tion for patients with cirrhosis and extreme obesity.

23 is associated with many diseases, including obesity.

24 e system in the inception and progression of obesity.

25 metabolism and is implicated in diet-induced obesity.

26 d protects from inflammation, steatosis, and obesity.

27 ycerides, and female-specific overweight and obesity.

28 ildren might not lower the risk of childhood obesity.

29 in fat intake and development of fat-induced obesity.

30 opportunity for preventing subsequent adult obesity.

31 limits its application for the treatment of obesity.

32 e immunity and metabolic disorders including obesity.

33 later life and is associated with childhood obesity.

34 set metabolic diseases, such as diabetes and obesity.

35 energy metabolism driving toward age-related obesity.

36 a-arrestin family previously linked to human obesity.

37 highly palatable food (HPF), that may drive obesity.

38 r that contributes to hedonic overeating and obesity.

39 een healthy individuals and individuals with obesity.

40 owth and protects against the development of obesity.

41 ltiple species, an effect that is blunted by obesity.

42 ion and timing in relation to overweight and obesity.

43 are selectively reduced in a mouse model of obesity.

44 and metabolic disease including diabetes and obesity.

45 n anabolic hormones, such as insulin, during obesity.

46 ful alcohol use, 1.4 (0.9-2.0, p = 0.10) and obesity, 1.4 (0.9-2.2, p = 0.13) We found no evidence th

47 the adjusted incidence rate among women with obesity (2.29 [95% CI, 2.02-2.56]), high triglycerides (

48 us physical activity) in pregnant women with obesity (294 contol, 263 intervention).

49 Cumulative incidence of obesity 5-years posttransplant was 24.1%.

50 nequality in the risk for obesity and severe obesity across GPS tenths.

51 were age, hypertension, diagnoses including obesity, alcohol, sleep apnea, diabetes, chronic obstruc

52 oth rodents and non-human primates, maternal obesity also predicts a preference for palatable foods i

53 e, we report on a monogenic form of IR-prone obesity, Alstrom syndrome (ALMS).

54 vascular diseases, type 2 diabetes mellitus, obesity, amnesia among other disorders.

55 quantify the potential benefit of decreasing obesity among at-risk women.

56 determined the incidence and risk factors of obesity among pediatric solid-organ transplant recipient

57 ta from Eurostat show that the prevalence of obesity among those aged 15-19 years remains under 5%, w

58 tients with coronavirus disease 2019 include obesity, an elevated d-dimer value, elevated C-reactive

59 In total, 281 incident cases of obesity and 777 cases of overweight were identified duri

60 elian randomization (MR) to evaluate whether obesity and AD are causally interlinked.

61 Likewise, both obesity and addictive behaviours have similar correlatio

62 e to exercise, yet chronically elevated with obesity and aging.

63 We also discuss the major contribution of obesity and alcohol to the ten most common cancers as we

64 With the rising rates of obesity and associated metabolic disorders, there is a g

65 uggest a neurobiological interaction between obesity and brain structure under physiological and path

66 s suggesting FABP4 as a novel player linking obesity and breast cancer risk.

67 mmune cells in human WAT under conditions of obesity and calorie restriction (CR) is not fully unders

68 dv36 seropositivity and its association with obesity and diabetes among adults attending a diabetes c

69 isease and general health conditions such as obesity and diabetes are closely linked by sharing commo

70 etween early-life nutrition and the risks of obesity and diabetes.

71 irubin levels are negatively associated with obesity and diabetes.

72 3 has been implicated in the pathogenesis of obesity and diabetes; however, the mechanisms and tissue

73 iota composition, and 4) prevent and reverse obesity and dysregulated glucose homeostasis in multiple

74 ze the transplant candidacy of patients with obesity and end-stage organ disease and improve perioper

75 In PDAC, obesity and excess fatty acids accelerate tumor growth a

76 A genetic predisposition, smoking, obesity and hormonal factors are established aetiologica

77 The mechanisms by which obesity and hypertension may synergistically induce macr

78 ffects of bariatric surgery on patients with obesity and hypertension remain uncertain.

79 ose tissue and protects mice from developing obesity and insulin resistance.

80 renders BAT as an attractive target against obesity and insulin resistance.

81 ut (Opn3-KO) mice were prone to diet-induced obesity and insulin resistance.

82 myeloid KLF2 protects mice from HFD-induced obesity and insulin resistance.

83 d energy expenditure is crucial to combating obesity and its comorbidities.

84 The escalating problem of obesity and its multiple metabolic and cardiovascular co

85 th brain-penetrant CB1R blockers, ameliorate obesity and its multiple metabolic complications.

86 factor 2 (KLF2) as an essential regulator of obesity and its sequelae.

87 h2b1/SNS/BAT/thermogenesis axis that combats obesity and metabolic disease.

88 s that have shown effects in mouse models of obesity and metabolic disorders, and how these might be

89 chedule is associated with increased risk of obesity and metabolic dysfunction in humans.(1-9) Howeve

90 ve, we highlight 1) the relationship between obesity and metabolic pathways putatively driving hepati

91 this field of research on innate immunity in obesity and metabolic perturbation, as well as future di

92 and April 2018, we randomized 24 adults with obesity and mild-moderate insulin resistance (homeostati

93 this has contributed to increasing rates of obesity and non-alcoholic fatty liver disease(2-4).

94 l upper airway soft tissues in subjects with obesity and OSA.

95 ity are associated with an increased risk of obesity and related metabolic disorders, but the role of

96 omes, 8 on cardiovascular disease, 3 each on obesity and rheumatoid arthritis, and 2 on chronic kidne

97 reveal a growing inequality in the risk for obesity and severe obesity across GPS tenths.

98 es evaluated the relationship between severe obesity and short-term outcomes and long-term mortality.

99 e impact of costly, chronic diseases such as obesity and substance use disorders.

100 findings shed light on the interplay between obesity and T2D in stroke recovery.

101 Obesity and type 2 diabetes mellitus are global emergenc

102 d is a promising target for the treatment of obesity and type 2 diabetes mellitus.

103 estinal microbiome have been associated with obesity and type 2 diabetes, in epidemiological studies

104 Here we seek to empirically test whether obesity and UE overlap behaviourally with addiction and

105 ic islets from obese animals and humans with obesity and/or T2DM.

106 icronutrient deficiencies, or on overweight, obesity, and dietary excess.

107 l to reduce the risk of both undernutrition, obesity, and DR-NCDs.

108 A subgroup of the Diet, Obesity, and Genes (DiOGenes) study (n = 209) was recrui

109 metabolic syndrome, hypertension, abdominal obesity, and hypertriglyceridemia.

110 the chronic inflammation observed in cancer, obesity, and other conditions.

111 Lifestyle, obesity, and the gut microbiome are important risk facto

112 -related, toxic and haemodynamic factors and obesity are also important causes of podocyte injury and

113 Although overweight and obesity are assumed to arise from an energy imbalance, e

114 Both aging and obesity are characterized by profound systemic metabolic

115 rrently, type 2 diabetes mellitus (T2DM) and obesity are major global public health issues, and their

116 Geographic remoteness and obesity are risk factors for specific causes of SCD in t

117 etabolic disorders, has been associated with obesity, arrhythmias, cardiac ischemia, insulin resistan

118 ere used to assess the role of pre-pregnancy obesity as a mediator in the association between materna

119 plays a central role in the pathogenesis of obesity as well as in the associated cardiovascular comp

120 ulin action that manifests with diet-induced obesity, as insulin action is preserved to protect funda

121 deficient (CysC knockout [KO]) mice worsened obesity-associated adipose tissue inflammation and dysfu

122 fatty acid binding protein (FABP4) promotes obesity-associated breast cancer development, thus sugge

123 rainstem, contributes to the pathogenesis of obesity-associated cerebrovascular dysfunction.

124 ipheral insulin-sensitive tissues and, thus, obesity-associated deterioration of glucose metabolism.

125 ntally validate the predicted function of an obesity-associated lncRNA, LINC01018, in regulating the

126 ovel viable approaches to prevent or relieve obesity-associated neuropathies.

127 molecular and cellular mechanism underlying Obesity-associated neuropathy and PNS dysfunction.

128 nificant pancreatic islet cell adaptation in obesity-associated tumors.

129 tion were significantly higher in women with obesity at the begining of pregnancy (mean difference: -

130 n health and disease with a special focus on obesity, bariatric surgery-induced weight loss, and immu

131 well as body mass index (BMI) as a marker of obesity (BMI > 30 kg/m(2)).

132 Obesity (BMI > 30 kg/m2) was more prevalent in the class

133 Obesity (BMI > 30) was significantly associated with cor

134 Seventy-one individuals with obesity (BMI: 34.6 +/- 3.4 kg/m2; age: 45.4 +/- 8.2 y; 3

135 nts and Main Results: Subjects with ARDS and obesity (BMI=57+/-12 kg/m(2)), following LRM, required a

136 trolled diabetes (hemoglobin A1c level >8%), obesity (body mass index >30), and depressive symptoms (

137 We assessed their penetrance and effect on obesity (body mass index [BMI] >= 30 kg/m2) in >450,000

138 could play a role in cancer etiology through obesity but also through inflammatory and oxidative mech

139 weight in patients with type 2 diabetes and obesity but have limited weight-lowering efficacy and mi

140 tively associated with adolescent overweight/obesity but not with suicidal ideation with planning.

141 Epidermal thickness did not differ with obesity but the expression of genes encoding proteins as

142 weight loss option for Veterans with severe obesity, but fewer than 0.1% of Veterans with severe obe

143 ed protein S-glutathionylation and developed obesity by an unknown mechanism.

144 to-high penetrance and increased the odds of obesity by more than 2-fold.

145 and epidermal FABP (E-FABP) in the fields of obesity, chronic inflammation, and cancer development.

146 In conclusion, CysC is upregulated under obesity conditions and thereby counteracts inflammation

147 ctal adenocarcinoma (PDAC), yet how and when obesity contributes to PDAC progression is not well unde

148 on, diabetes with chronic complications, and obesity demonstrated age-dependent effects, with the hig

149 t may protect against this drive and prevent obesity development.

150 g pregnancy is rising as older maternal age, obesity, diabetes mellitus and hypertension become more

151 Mid-life metabolic disease (ie, obesity, diabetes, and prediabetes) causes vascular dysf

152 n considered a culprit in the development of obesity/diabetes mellitus-induced cardiomyopathy.

153 as a research tool for diagnostic imaging of obesity/diabetes, bacterial infection, and cancer.

154 Obesity/diabetes-associated liver tumors are specificall

155 Adults with obesity diagnosis who underwent primary bariatric surger

156 Its reduced levels in diet-induced obesity (DIO) contribute to hyperleptinemia and leptin r

157 Obesity disrupts physiological homeostasis and alters bo

158 Individuals with obesity do not represent a homogeneous group in terms of

159 eworthy because they may in part explain how obesity drives colon cancer progression.

160 al therapeutic target of anticancer and anti-obesity drugs by inhibiting its DNA-binding activities.

161 For HbA1c, however, the association with obesity duration persisted, independent of obesity sever

162 ally adjusted models, male sex, underweight, obesity, education, poor self-rated health, television-v

163 nd how macrophage-driven inflammation due to obesity enhances tumor formation, mice were treated with

164 nts could inform policies for control of the obesity epidemic in India and other urbanising LMICs.

165 results agree with previous reports showing obesity exacerbates AD-related pathology and symptoms in

166 pe 2 diabetes mellitus, ubiquitous abdominal obesity, exposure to the world's highest levels of air p

167 oss BMI groups, except in women with class 3 obesity, for whom low weight gain and weight loss may be

168 Participants with class III obesity had a greater risk of metabolic syndrome than th

169 Childhood obesity has become a global pandemic in developed countr

170 Obesity has been firmly established as a major risk fact

171 Obesity has tripled worldwide since 1975 as environments

172 lationships between gut microbiome and PN in obesity have yet to be explored.

173 tive association between plasma ANGPTL5, and obesity, high sensitivity C-reactive protein (HsCRP) and

174 NAFLD is associated with obesity; however, it can occur in normoweight (lean) pat

175 that subsequently inhibit food consumption, obesity, hyperglycemia, and liver steatosis in HFD-treat

176 for established CKD risk factors, including obesity, hypertension, and type 2 diabetes.

177 tal heart disease, various cardiomyopathies, obesity, hypertension, diabetes, and chronic kidney dise

178 he influence of the metabolic syndrome (MS) (obesity, hypertension, elevated triglycerides, reduced l

179 Patterns of reporting for obesity, hypertension, heart conditions, or hypercholest

180 Emerging evidence suggests that obesity impacts brain physiology at multiple levels.

181 n of P2Y(6)R protects mice from diet-induced obesity, improving glucose tolerance and insulin sensiti

182 PWS are replaced with excessive feeding and obesity in childhood through adulthood.

183 The prevalence of obesity in children and adolescents worldwide has quadru

184 Using a high-fat diet model of obesity in mice and breast tissue from women, we observe

185 urons during the development of diet-induced obesity in mice.

186 entify the prevalence of hypoalbuminemia and obesity in orthopaedic trauma patients with high-energy

187 ative stress and point to a critical role of obesity in T2DM cardiomyopathy.

188 d explore potential interventions to address obesity in these populations.

189 2015-2018 the US prevalence of youth severe obesity increased in Hispanics and non-Hispanic blacks (

190 2 in macrophage activation in the context of obesity-induced adipose tissue inflammation and insulin

191 lium-dependent vasodilation is a hallmark of obesity-induced hypertension.

192 al women seem to be generally protected from obesity-induced metabolic and cardiovascular complicatio

193 However, the mechanism by which HFD/obesity induces chondrocyte apoptosis is not clearly und

194 We hypothesized that unique obesity-inflammation HFpEF phenotypes exist and are asso

195 Obesity influences asthma severity and may impair respon

196 Oral administration of UAB126 ameliorated obesity, insulin resistance, hepatic steatosis, and hype

197 In addition, a significant age-by-obesity interaction on cortical thickness emerged driven

198 Despite the rising incidence of childhood obesity, international data from Eurostat show that the

199 tissue integrity, and beta-cell mass during obesity is a major challenge.

200 Obesity is a major modifiable risk factor for pancreatic

201 Although obesity is an established risk factor for morbidity and

202 Obesity is an important independent risk factor for seve

203 t increased insulin secretion in people with obesity is associated with excess adiposity itself and i

204 We hypothesize that this obesity is caused by TH(+) cell loss or altered phenotyp

205 Severe obesity is characterized by specific additional cardiova

206 earch should put to rest the contention that obesity is common in severe COVID-19 because it is commo

207 tients with myocardial infarction and severe obesity is increasing and there is a lack of evidence ho

208 Obesity is known to increase breast cancer incidence and

209 ed from transplantation until development of obesity, last follow-up, or end of study.

210 drupled since 1975 and is a key predictor of obesity later in life.

211 (primary cause) with multiple sclerosis and obesity listed as secondary causes.

212 Here we show that during obesity MAIT cells promote inflammation in both adipose

213 Obesity may contribute to adverse outcomes in coronaviru

214 gest that interaction between gingivitis and obesity may exhibit disease reciprocity in which activat

215 Our findings suggest that obesity may indeed be related to an imbalance in behavio

216 en the PRSBMI, eating behavior patterns, and obesity measures.

217 vestigated the extent to which pre-pregnancy obesity mediates the association between maternal place

218 hway of asthma pathogenesis in patients with obesity/metabolic syndrome, in which the GRK2-mediated s

219 Stable metabolically unhealthy overweight or obesity (MUOO) (HR 2.22, 95% confidence interval [CI] 2.

220 moderate (type 2 diabetes, n = 9), or mild (obesity, n = 8).

221 roportions with the increasing prevalence of obesity, nonalcoholic liver disease, and alcohol overuse

222 Analysis indicated a significant impact of obesity on gingivitis.

223 We review the impact of obesity on kidney, liver, and cardiothoracic transplant

224 transplantation recapitulated the effects of obesity on microglial activation and IL-1beta gene expre

225 preventing the negative effects of maternal obesity on offspring development and adult health.

226 owever, we don't understand the influence of obesity on susceptibility to infection or on non-severe

227 IF1L is not essential for the development of obesity or impaired glucose handling due to HFD, and adv

228 lead to several metabolic diseases including obesity or type 2 diabetes.

229 weeks either a high-fat diet (HFD) to induce obesity, or chow as reference group.

230 tigates how changes in population weight and obesity over time are associated with genetic predisposi

231 Finally, the obesity paradox was not observed after including Acute P

232 the prevention of diseases such as diabetes, obesity, Parkinson's, Alzheimer's, and others.

233 Obesity plays a profound role in risk for death from COV

234 dle-aged mice, we modeled metabolic disease (obesity/prediabetes) via chronic high-fat (HF) diet and

235 riation in underweight and overweight and/or obesity prevalence in the country, adjusted for cluster

236 rs and consider future priorities for global obesity prevention.

237 fying them as a novel therapeutic target for obesity-related asthma, a disease that is suboptimally r

238 gested a modest association for leucine with obesity-related cancers (1.04 [1.00-1.08]), and no assoc

239 on in obese AT, lending further insight into obesity-related comorbidities in humans.

240 of 40 or higher or 35 or higher with serious obesity-related comorbidities.

241 lular metabolism are unclear but relevant to obesity-related diseases.

242 myeloid leukemia, debilitating fibroses, and obesity-related liver dysfunction.

243 mation (metaflammation) is characteristic of obesity-related metabolic disorders, associated with inc

244 ntial outcome approach was used to determine obesity-related periodontitis risk using the Australian

245 To avoid the confounding effect of obesity-related steatosis, only 70 individuals who had c

246 tion analysis including 21 inversions and 25 obesity-related traits on a total of 408,898 Europeans a

247 relationship between mean adipocyte area and obesity-related traits, and identify genetic factors ass

248 Obesity remains a risk factor for CVD independent of maj

249 of genetic regulation of leptin in polygenic obesity remains poorly understood.

250 the activity of these circuits is altered in obesity remains poorly understood.

251 We find that obesity-repressed LincIRS2 is controlled by MAFG and obs

252 rate the need for sex-specific approaches in obesity research and potentially treatment.

253 d as a prophylactic therapy for diabetes and obesity, respectively.

254 A prominent hypothesis is that people with obesity respond to rewards similarly to people with addi

255 dministration of FMT capsules in adults with obesity results in gut microbiota engraftment in most re

256 Its expansion in obesity results in increased mortality and morbidity, wi

257 h obesity duration persisted, independent of obesity severity.

258 ocarcinoma, such as older age, male sex, and obesity, should undergo endoscopy.

259 Obesity significantly enhanced the incidence of tumors o

260 x and gestational weight gain predict future obesity status of the offspring.

261 m p62 deficiency is manifest after birth and obesity subsequently develops despite normal food intake

262 4 to 8 times larger projected impact against obesity than would be achieved though reformulation alon

263 es define microenvironmental consequences of obesity that foster tumorigenesis rather than new driver

264 the presence of metabolic stress, such as in obesity, the resulting degradation products may play a d

265 f Medical Officer to combat rising levels of obesity-the highest of any country in the west.

266 ogram and may present as a future target for obesity therapeutics.

267 For middle aged and older adults with obesity there was also a slight increase in susceptibili

268 r microstructure in children with overweight/obesity; those findings indicate that the association of

269 Here, we used a mouse model of maternal obesity to investigate the importance of early life ER s

270 Obesity, tobacco smoking, and genetic predisposition inc

271 Models included adjustment for race, obesity, tobacco use, hypertension (HTN), atrial fibrill

272 high-intensity, lifestyle-based program for obesity treatment delivered in primary care clinics in w

273 This review addresses the interplay between obesity, type 2 diabetes mellitus, and cardiovascular di

274 a potential target to decrease the risks of obesity, type 2 diabetes, and cardiovascular disease, an

275 e is now recognized as a key risk factor for obesity, type 2 diabetes, and cardiovascular diseases.

276 ng pancreatic cancer include family history, obesity, type 2 diabetes, and tobacco use.

277 of metabolic diseases (hypertriglyceridemia, obesity, type 2 diabetes, hypertension, metabolic syndro

278 but fewer than 0.1% of Veterans with severe obesity undergo it.

279 cardiovascular and cerebrovascular disease, obesity, undernutrition, or hypercholesterolemia.

280 we highlight variants in candidate genes for obesity warranting further investigation.

281 portion of T2DM incident cases attributed to obesity was 55.6% in 1990, 59.5% in 2020, and 62.6% in 2

282 Among adults with H1N1pdm infection, obesity was associated with increased likelihood of symp

283 Recipient obesity was defined as body mass index (BMI) >35 adjuste

284 Maternal obesity was established by prepregnant HF (ppHF) feeding

285 Donor severe obesity was not associated with adverse post-transplant

286 rts, we investigated whether the duration of obesity was related to heterogeneity in cardiometabolic

287 However, the risk of obesity was significantly higher in the sub-analysis of

288 ncrease in the average BMI and prevalence of obesity was steeper among the genetically predisposed.

289 on identifying the genetic susceptibility to obesity, we performed a GWAS on metabolically healthy th

290 Male sex, older age, and obesity were associated with higher concentrations of in

291 OR of sarcopenic obesity were higher for men 2.17 (1.70-2.76), those repo

292 The effects of gingivitis on obesity were in the same direction but generally not sta

293 hypertension with chronic complications, and obesity were risk factors in most age-groups, with highe

294 ome, Charlson Comorbidity Index, diabetes or obesity when compared to no-CCY (all P > 0.05), but were

295 ght loss on insulin secretion in people with obesity who did not improve insulin sensitivity despite

296 oV-2 burden, demographic characteristics and obesity with a minor contribution of chronic comorbid co

297 To detect obesity with body mass index (BMI), the meta-analyses re

298 trongly associated with the co-occurrence of obesity with other common diseases.

299 ese findings provide one explanation for how obesity worsens cancer outcomes and may point to a new m

300 ings in a cohort of children with overweight/obesity, young adults and middle-age adults.